期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿托伐他汀对高血压肾损害尿蛋白的影响研究

暂未订购
导出
摘要 目的:研究阿托伐他汀(立普妥)对血压控制正常的高血压肾损害患者尿蛋白的影响。方法:80例血压控制正常的高血压肾损害患者随机分为阿托伐他汀组(40例)或对照组(40例),分别给予阿托伐他汀(20mg)或安慰剂治疗6个月,观察血压(SBP/DBP),血脂(TG、TC、HDL-C、LDL-C)、肌酐(Cr)、24h尿蛋白(U-Pro)变化。结果:治疗6月后,阿托伐他汀组的Tc、LDL-C、U-Pro较对照组均显著降低(P<0.05),而两组间的SBP/DBP、TG、Cr无明显改变(P>0.05)。结论:阿托伐他汀可明显减少高血压肾损害的尿蛋白。
作者 饶隽 陈良海
机构地区 四川省第五人民医院内科 泸州医学院附属医院心内科
出处 《泸州医学院学报》 2009年第4期427-428,共2页 Journal of Luzhou Medical College
关键词 阿托伐他汀 尿蛋白 高血压
分类号 R544.1 [医药卫生—心血管疾病]
  • 相关文献

参考文献7

  • 1李为民,孔一慧.他汀类药物治疗慢性心力衰竭的利弊探讨[J].中华心血管病杂志,2006,34(9):774-775. 被引量：28
  • 2赵运涛,傅向华.他汀类药物抗炎作用的循证医学证据[J].心血管病学进展,2005,26(4):387-389. 被引量：12
  • 3无.慢性稳定性心绞痛诊断与治疗指南[J].中华心血管病杂志,2007,35(3):195-206. 被引量：2190
  • 4Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3meth-ylglutaryl coenzyme a reductase inhibitors on renal function[J]. Am J Kidney dis, 2005;45:2.
  • 5Lee TM, Su SF , Tsai CH. Effect of pravastatin on proteinuria in patients with well-controlled hypertension [J]. Hypertension, 2002 ; 40:67.
  • 6Park J K, Muller DN, Mervaala EM, et al. Cerivastatin prevents angiotensin Ⅱ induced renal injury independent of blood pressure and cholesterol-lowering effects[J]. Kidney Int, 2000;58:1420.
  • 7Bianchi S, Bigazzi R, Caiazza A, et al. A controlled prospective study of the effects of atorvastiatin on proteinuria and progression of kidney diseasc [J]. Am J Kidney Dis, 2003 ; 41:565.

二级参考文献76

  • 1Braunwald E.Cardiovascular medicine at the turn of the millennium:triumphs,concerns,and opportunities[J].N Engl J Med,1997,337:1360-1369.
  • 2Heart Protection Study Collaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals:a randomized placebo-controlled trial[J].Lancet,2002,360:7-22.
  • 3The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID)Study Group.Prevention of cardiovascular events and death with pravastatin inpatients with coronary heart disease and a broad range of initial cholesterol lev-els[J].N Engl J Med,1998,339:1349-1357.
  • 4Downs JR,Clearfield M,Weis S,et al.For the AFCAPS/TexCAPS Research Group,Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:results of AFCAPS/TexCAPS[J].JAMA,1998,279:1615-1622.
  • 5Sever PS,Dahlof B,Poulter NR,et al.For the ASCOT Investigators.Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations,in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):a multicentre randomized controlled trial[J].Lancet,2003,361:1149-1158.
  • 6Stein DT,Devaraj S,Balis D,et al.Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia[J].Arterioscler Thromb Vasc Biol,2001,21:2026-2031.
  • 7Wolfrum S,Jensen KS,Liao JK.Endothelium-dependent effects of statins[J].Arterioscler Thromb Vasc Biol,2003,23:1-8.
  • 8Takemoto M,Liao JK.Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors[J].Arterioscler Thromb Vasc Biol,2001,21:1712-1719.
  • 9Rasmussen LM,Hansen PR,Nabipour MT,et al.Diverse effects of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase on the expression of VCAM-1 and E-selectin in endothelial cells[J].Biochem J,2001,360:363-370.
  • 10Rosenson RS,Tangney CC,Casey LC.Inhibition of proinflammatory cytokine production by pravastatin[J].Lancet,1999,353:983-984.

共引文献2221

泸州医学院学报
2009年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部